The aim is to discuss the various forms of bias in surgical research, including how it impacts validity and how to recognize and avoid it. Methods: The various factors affecting bias in surgical research's design, execution, and reporting were explored. The impact of these factors on internal and external validity in both observational and randomized controlled trials was examined, and recommendations were made for ameliorating the various biases. Results: Identifying bias when interpreting a trial enables surgeons to assess surgical research's internal and external validity. Avoiding bias and/or using methods that minimize bias helps surgeons design and conduct trials with enhanced validity, which can be reliably translated into practice. To accomplish this, surgeons need to be cognizant of susceptibility bias, the applicability of surrogate endpoints, and the use of inappropriate comparators in trial design. They must also be aware of detection, ascertainment, performance and transfer bias in trial execution, and of citation bias in trial reporting. Conclusions: Familiarity with clinical trials' potential biases helps surgeons assess the believability and applicability of research results. Though these biases may sometimes be ameliorated by randomization, blinding, and intervention standardization, these remedies can present distinctive problems to surgical research. This poses a unique need and opportunity for innovation in surgical research design and evaluation. It necessitates that further research be done on methods to improve not only the internal and external validity of surgical trials but also their assessment.
INTERNAL AND EXTERNAL VALIDITY
To assess research's usefulness to them and to their patients, surgeons ask: (1) are these conclusions believable and (2) how does this research apply to my practice. The first question concerns the scientific integrity of the research itself, its internal validity; the second applies to the research's generalizability, its external validity.
A study's internal validity is the accuracy of its conclusions about an intervention's effects on a given group of subjects under a study's specific circumstances. It depends on both a trial's design and conduct. For a study to have internal validity, the difference in the interventions should be the sole source of the outcome differences. A study may lack internal validity if the differing outcomes are due to factors other than the difference in the interventions. Such factors might be unequal distributions of prognostically important subject characteristics, differences in intervention delivery, or inconsistent measurement of significant elements such as comorbidities or outcomes. This type of lack of control creates a bias that undermines a clinician's ability to trust that what the study says is true. It is the crux of internal validity. Consider a study to determine the different infection rates in traumatic hand wounds irrigated with normal saline or with an antibiotic solution. The antibiotic solution is prepackaged with a propulsion device. The saline is delivered by hand with a 50-mL syringe. The outcome, infection, is defined as persistent wound drainage at 6 weeks. The study finds significant differences between the 2 groups, concluding that 1 solution is better at preventing infection in traumatic hand wounds than the other. Was this study designed and conducted in a way to produce believable results? Does it have internal validity? Could the difference be due to factors other than the different solutions, such as the different solution delivery methods, the different solution volumes used, the lack of blinding of the evaluators and surgeons, and the definition of infection that was used? There are too many potential biases in this study to say that it has proved what it concludes. It lacks internal validity.
External validity deals with the applicability of a study's conclusions to the real world, beyond the conditions imposed by the trial. This is the generalizability of research, how a clinician can rely on research conclusions to apply to patients in his/her practice. Sometimes referred to as research translation, it depends not only on a trial's design and conduct but also on how it is reported. Studies that lack internal validity do not produce reliable evidence and so cannot be generalized; they have no external validity. But internally valid studies can lack external validity if they leave clinicians unable to judge if and when they should use the knowledge generated by them or if the trial's conditions have been defined in a way that makes them inapplicable to practice outside the trial. Consider the same hand wound irrigation study, this time with internal validity-the irrigating solutions are delivered in the same way and in the same volume, follow-up is for 1 year and includes x-rays sent to a central reading site and everyone is blinded. Dr. Smith decides to change to the more favorable solution. After 1 year, she looks at her results and is disappointed to find them unchanged from before and much worse than the study predicted. Why? Perhaps her patient population differs in important ways from those in the study, perhaps there are significant differences in her treatment regimen. She cannot tell because there are insufficient details in the study report to tell her about the nature of the study patients and their wounds and about the operative and postoperative regimen. In her practice, the results of this internally valid study are externally invalid. Because she and her patients do not benefit from the study results, she becomes reluctant to apply what she reads in the literature. It is this lack of external validity that is thought to be a major reason why clinicians often do not use treatments that research shows to be superior. 2 Bias compromises both external and internal validity. It is a systematic error, which undermines a study's ability to approximate the truth. Bias may occur when setting up and conducting a trial, in interpreting a trial's results, or after a trial is completed. It may be enabled and/or facilitated by factors outside the trial. It can be unconscious or deliberate, even unavoidable. It is not chance variability.
Bias has many forms, some of which are subtle and difficult to detect without careful scrutiny. An awareness of bias's diverse forms can help a physician judge both the internal and external validity of a study. This article will examine the various types of bias and how they occur, especially in surgical research, and how they can be detected and avoided. Only by knowing how to recognize and assess bias can surgeons reliably apply research results to their practices.
BIAS BEFORE A TRIAL BEGINS

Susceptibility Biases
Research measures the effectiveness of one intervention relative to another by comparing different intervention groups' outcomes. If different study groups have prognostic features that unequally increase/decrease risk to 1 group, making 1 group more/less susceptible to disease progression, and/or undesirable effects from an intervention, a study has susceptibility bias (Table 1) .
Selection criteria are necessary to minimize group variability so that statistically valid conclusions can be reached in a reasonably sized sample. But if selection criteria have prognostic importance, they create a type of susceptibility bias called selection bias. 3 For instance, in a study exploring wound infection rate differences in patients having an inguinal hernia repair either laparoscopically or via an open procedure, a selection criterion is a body mass index (BMI) Ͼ30. Because obesity increases wound infection rates more in open procedures than in laparoscopic ones, this criterion biases the results in favor of the laparoscopic repair. 4, 5 It compromises internal validity.
It is impossible to recognize or test for all prognostic variables. To avoid inadvertent selection bias it is best to prospectively assign subjects to different treatment groups in a purely random fashion, as in a randomized controlled trial (RCT). This reduces imbalances in baseline variability, including unknown prognostic factors. 6 The successful conduct of RCTs requires that both investigators and participants have equipoise, a genuine uncertainty about which treatment is best. Achieving equipoise has been especially difficult for surgeon-investigators and their patient-subjects. [7] [8] [9] [10] [11] For instance, in 1976, the National Surgical Adjuvant Project for Breast and Bowel Cancer cooperative group (NSABP) launched an RCT to compare the effectiveness of 3 breast cancer treatment regimens: segmental mastectomy, segmental mastectomy with radiation, and total mastectomy. 12 When enrollment was unexpectedly slow, the principal investigators were surveyed. The most prevalent reasons for not enrolling subjects were surgeons' discomfort with randomization, their inability to separate their roles of researcher and physician, and their discomfort in discussing uncertainty. These manifest surgeons' uneasiness with equipoise. Indeed, because of their disquiet, only 27% of the 91 responding surgeons enrolled all their patients in the RCT, and 38% enrolled only some. By picking and choosing a subset of eligible patients, they may have created selection bias within the RCT 13 at least partially because they lacked equipoise. Such actions compromise both external and internal validity.
If a subject characteristic, such as BMI, is thought to have prognostic significance, groups can be stratified by that feature, or confounder (factor with the potential to produce bias), so that the group with that trait has a separate randomization schedule. 14 In the hypothetical inguinal hernia repair study, the groups could be stratified by subjects with a BMI Ͼ30 and Ͻ30, to create sub-groups for analysis, though at the risk of creating sample size differences that might affect statistical significance. This would create an internally valid study that would produce reliable evidence about wound infection rates with both techniques for both groups of patients. 15 Another form of susceptibility bias is channeling bias. It occurs if patients are assigned to an intervention on the basis of prognostic factors. Ethical concerns that one intervention is too risky for some subjects can be a valid reason for specifying that subjects with certain characteristics receive a given intervention rather than randomizing them as in an RCT. 16 An example would be a study comparing longevity after carotid endarterectomy and carotid stenting, in which subjects considered too sick for general anesthesia were excluded from the endarterectomy group, resulting in the sickest subjects being in the stent group. There are statistical techniques that can be used to try to control for such prognostic differences in subject selection; however, they usually require a larger sample size to achieve statistical significance than would otherwise be predicted.
Because RCTs are difficult and costly to do, a test group is often compared with a retrospective or concurrent nonrandomized control group such as a registry. As with concurrent controls, biases occur if the 2 groups have features of differing prognostic importance. It can be almost impossible to unearth such baseline variability, and therefore to control for it, in retrospective controls because determining nonconcurrent control characteristics is rarely possible.
Studies using a historical comparator group often have chronology bias, a bias that occurs because of changes over time, which affect outcome. Such changes can occur in the way treatments are delivered, diseases are detected, or even in the methods used to measure variables or outcome. Because so many factors besides the surgical intervention itself can affect surgical outcomes, changes in the surgical environment must also be considered. Some of these might be anesthesia advances, like more sophisticated monitoring systems, or ancillary instrumentation, like better lighting systems, or postoperative care changes, such as more effective antiemetics. All these can make chronology bias a significant factor in surgical research using historical comparators, 6 affecting both internal and external validity. An example is a retrospective observational study that was done over 14 years to compare shortand long-term outcomes of simple linear repair and endoventricular patch plasty (EVPP) for postinfarction left ventricular aneurysm. Most linear repairs were done in the early years and the EVPPs in the later years. Outcomes were statistically better in the EVPP group. The authors noted that one reason for this might have been the more prevalent use of intra-aortic balloon pumps in the later years and the cardiac team's increasing expertise. These time-related factors affected primarily the EVPPs. 17 Other time-related factors such as instrumentation changes other than the intra-aortic balloon pumps, development of better anesthesia monitoring equipment, etc, might also have contributed. Because multiple factors are involved, it is not always possible to control for chronology bias in surgical research.
If a group other than a randomized concurrent group is being compared with a test group, it is important to know why that comparator group was chosen and to know more about it than its obvious sources of potential bias. Nonconcurrent comparators can differ from a test group for many reasons such as different practice patterns, who seeks care or an environment's policy decisions. 18 As an example, in Canada, where waiting lists and government policies control access to care, who gets elective surgery is different than in the United States, where insurance coverage determines it. Differences in the selection of who gets surgery can create susceptibility bias.
In summary, susceptibility biases can be created by selection criteria, by channeling, or by other confounding factors as well as by various features of an inappropriate comparator group. If the source of bias, the prognostic feature that impacts outcome, is identifiable and able to be measured in all groups, as with some selection criteria, it can sometimes be controlled for by stratification or other analysis techniques. This is most feasible when concurrent groups are compared. Only randomization controls for unidentifiable prognostic features that might create bias. But randomization alone cannot control for all biases that may affect either internal or external validity (Table 1) .
Design Biases
Before the first subject is enrolled, various design features beyond subject susceptibility can establish an environment that facilitates or deters bias ( Table 2) . Whether a study is observational or an RCT, the more well-defined its design when it begins the less likelihood there is for bias. Flexibility in design, such as vague definitions of outcome or analysis methods, encourages bias 19 by enabling investigators to manipulate a study to obtain an answer they want or think they should get instead of objectively unearthing it. That said, in surgical research, which often involves several surgeons at different sites, there often is, necessarily, some design variation. For instance, in the NETT RCT that compared surgical lung reduction to best medical management for COPD, the stapled wedge lung resection could be done either through a median sternotomy or as video-assisted surgery. 20 That study's goal was not to compare the results of a type of procedure; it was to compare the outcomes of usual surgical intervention methods and medical management. This design improved external validity by testing scenarios-different surgeons do things differently to achieve the same goal-which easily translated into the reality of surgical practice. How tightly a surgical research procedure should be controlled depends on the question being asked. Variability must be limited to achieve internal validity but, to reflect actual surgical practice, there must be sufficient variability to produce external validity. Balancing these 2 requirements is a significant surgical research challenge. It must be considered and addressed in a protocol's design before a trial begins.
A trial design factor that can contribute to bias is the use of surrogate endpoints. Collecting clinical endpoints such as death, disease recurrence, or reoperation can require many years-at which point the intervention being studied may no longer be in use. Surrogate endpoints save costs and time. Their disadvantages can be the uncertainty about their correlation to significant clinical outcomes, their inability to give an accurate picture of complications, especially long-term ones and, their inability, because they measure short-term changes, to address long-term effects such as implant longevity and, the variable ways in which they are measured. 21 For instance, in cardiovascular intervention studies, coronary angiograms are often a surrogate endpoint for subsequent myocardial infarction reduction. Though less expensive than following patients until they have a cardiovascular event, there is little correlation between the degree of stenosis seen on coronary angiogram and subsequent myocardial infarction. 22 Surrogate endpoints that have been proven to reliably correspond to pertinent clinical outcomes, which are known to have a strong biologic rationale, and, if possible, a quantitative relationship to the relevant clinical outcome, can greatly minimize this potential for bias. 23 As with clinical endpoints, whenever surrogate endpoint measurements are made, they need to be done and interpreted in a consistent manner. In the case of surrogate endpoints that means standardizing measuring equipment and surrogate endpoint interpretation. Surgeons who apply a study with a surrogate endpoint to their practice should consider the validity of the surrogate endpoint and remember that such studies may give an incomplete picture of an intervention, especially its long-term effects and complications. Though a study using a surrogate endpoint may have internal validity, if that endpoint does not translate into a relevant clinical outcome, the study does not have external validity.
BIAS DURING TRIAL EXECUTION
Though trial design lays the foundation for encouraging or discouraging bias, bias can also be produced during the course of a trial. Any potential for bias that exists within a trial's design may be exacerbated or ameliorated by how a trial is carried out.
Information Biases
Information biases occur if critical information is distorted or compared information is mismatched, creating study data inconsistencies. This can occur within a group or in the comparison between a test and comparator group. It affects internal validity. It occurs in both observational studies and RCTs. Two forms of information bias are detection bias and ascertainment bias (Table 3) .
Detection bias occurs if the methods for measuring outcome are not uniform either within a study or between a test and a comparator group. Vaguely defined outcomes, unblinded evaluators and subjects, and unreliable surrogate endpoints facilitate it.
14 For instance, in a trial comparing the esthetic result of submuscular to subglandular breast augmentation, where a naturally shaped breast when standing is the outcome measurement, an evaluator's nonstandardized individual concept of beauty may influence outcome. Such subjective assessment creates a nonuniform outcome measurement. A more reliable outcome measurement would result if multiple evaluators, preferably with varying opinions about beauty, were employed, using a grading system based on their degree of concurrence. This might not eliminate bias because of the subjective nature of the evaluation but could curtail it by mitigating personal opinion.
Even when endpoints, whether clinical or surrogate, are appropriate and clearly specified, assessment can be biased. Blinding both evaluators and subjects may reduce bias especially when evaluating outcomes with intermittent or subjective features such as pain. 24 Evaluator blinding guards against an investigator, consciously or subconsciously, misinterpreting a subject's state, eliciting a more/less favorable response or manipulating data. It prevents subjects from producing a better result because they hope, or trust, a treatment will work or to please an investigator. 6 For instance, if the outcome of a knee procedure is range of motion, subjects can be encouraged, or may push themselves, to make more/less effort to increase/decrease their range of motion. Though surgery's nature often makes blinding difficult, even impossible, it should be incorporated into surgical RCTs if feasible. This may require that an evaluator be other than the operating surgeon-researcher. Because of their nature, it is not something that can be done in observational trials.
Detection bias may also occur if outcomes are measured differently in a test and nonconcurrent comparator group, especially if surrogate endpoints are not measured in exactly the same way in both groups. For reasons already discussed, this is especially likely to be a problem with historical controls. Similarly, blinding evaluators and/or subjects in 1 study but not in the other may bias outcome comparison. Subjects who know which treatment they received, as in the knee range of motion example, may differ from those who do not in how they report beneficial and/or harmful effects, and in their tendency to seek treatment outside of a study and/or in their rate of dropping out of a study. 24 In distinction to detection bias, ascertainment bias results from a distorted determination of exposure to a factor that is important in a study. This can compromise the reliability of selection criteria or other factors related to outcome interpretation. For instance, if a pivotal information item is based on remembering previous events, recall bias, a type of ascertainment bias critical to some types of research, can occur. Subjects with a disease tend to seek a reason for that disease, whereas with no motivation for such reflection, healthy individuals are less likely to recall such events. 25 For instance, recall-based studies suggested a correlation between prior abortion and breast cancer. When centralized medical records, instead of recall, were used to obtain abortion history, there was no such correlation. 26 -28 Family history recall 
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can also be a form of recall bias. Individuals with a disease are more likely to recall another family member with the same, or what they interpret as the same disease, than are individuals without that disease. 15 For example, subjects with rheumatoid arthritis are more likely to remember an ancestor with arthritis interpreted as rheumatoid arthritis, than are those not affected. 25 Because observation studies often gather data that relies on recall, they are especially prone to ascertainment bias.
Biases resulting from information errors can be reduced if the errors occur randomly in both comparison groups. This is facilitated by evaluator blinding and comparing concurrent groups, if possible randomized ones.
Transfer Bias
Transfer bias occurs when a study feature causes intervention groups to have unequal follow-up losses. This happens if one study group has features that discourage follow-up. For instance, one group may have such good short-term outcomes that many of that group's subjects see no need to return for follow-up, or conversely, such bad outcomes that many won't return for follow-up. This can lead to unequal information deficiencies, affecting data collection reliability, and biasing the outcomes analysis to favor one group more than another. Putting measures in place to achieve better follow-up by minimizing follow-up burdens can reduce this possibility.
14 Such measures might include arranging follow-up at convenient places and times, covering expenses such as parking, even offering incentive payments for follow-up visits (Table 4) . RCTs, which are often of short duration, are less likely to have this problem, but they are also less likely than longer duration observational studies to produce critical information about long-term effects, and for surgeons in particular, about issues related to implant longevity.
Performance Bias
Performance bias occurs when procedures or interventions are not performed in a uniform way. It affects internal validity. Though performance bias may exist in any type of study, it is especially a problem in surgical studies. Certainly no 2 surgeons perform a procedure exactly the same way, nor does a surgeon do a given procedure in an identical manner each time (Table 4) . Similarly, perioperative care, including anesthesia, may vary in different institutions. A reasonable degree of variation exists in all trials. It might even be considered necessary in surgical trials to demonstrate external validity, the ability of the study results to be translated into a variety of surgical practices. But sometimes these variations can affect internal validity. One way to correct for that is to stratify subjects by center, surgeon, or surgeon characteristics. That surgical procedures cannot be standardized in the same way as medications is not a justification to design a protocol so loosely that it disregards reasonable uniformity in surgical execution. Instead, it should be seen as an opportunity to think beyond the prototypical pharmaceutical trial to creatively design surgical trials that minimize distracting variability while maintaining sufficient performance variation for external validity.
Given the evidence that surgical experience can impact outcomes, one source of variability that may need to be controlled for in surgical trials, especially RCTs, is surgeons' diverse experience with a given procedure. A surgeon may not routinely do a procedure because it is not his/her preferred procedure for a given condition or because his/her patient volume for that particular condition is such that he/she rarely needs to do the procedure. It may also occur because a procedure is innovative in some way, as and when a new instrument or implant is used, or a technique is modified significantly. 14 The effect of experience with a given procedure, even an innovative one, can be difficult to ascertain in advance. Neumayer et al conducted a study at 14 Veterans Affairs hospitals comparing inguinal hernia recurrence rates in open mesh and laparoscopic mesh repairs. For surgeons who had performed more than 250 laparoscopic repairs, the recurrence rate was significantly less than for those who had performed less than 250. But for open repairs, there was no difference between the more and less experienced surgeons. 29, 30 If a trial involves surgeons with varying significant experience, populations can be stratified by the surgical experience level during analysis to determine experience's significance. If, before an RCT begins, it is suspected or known that the amount of experience is important, a trial may require surgeons or centers to have a certain amount of experience to enroll subjects. In the case of innovative procedures or instrumentation, trials often use a run-in phase, with surgeons performing a certain number of procedures or meeting some performance benchmark before subjects are used in the statistical analysis.
14 This may have implications for external validity, which should be remembered when translating a new procedure into clinical practice.
One way to deal with performance bias is to allocate procedure groups by surgeon. 31, 32 In this scenario, each surgeon performs the procedure he/she usually does creating groups of concurrently treated subjects to compare as a way of comparing interventions. Such a design, by simulating a normal patient-physician relationship, makes surgeons' and patients' acceptance of equipoise easier. To minimize design bias, such nonrandomized trials should be designed so that all protocol components, including inclusion criteria, data collection methods, outcome determination, and follow-up are standardized and determined in advance.
14 Such a design was used to assess different treatments' outcomes for Legg-Calvé-Perthes disease. In this prospective multicenter controlled nonrandomized study, subjects were allocated to 5 different interventions, not all involving surgery. 33 That surgeons performed the procedure with which they were most familiar creates external validity problems if the results are interpreted to mean that in all hands a given procedure will be best for a given group of patients. This is something surgeons must weigh when they consider applying a surgical technique to their own practices-how might this work for my patients in my hands, in my setting. Because subjects are not allocated by chance in such nonrandomized trials, there can be significant variability between groups, creating selection bias. instance, if one surgeon's practice attracts recent immigrants, this may result in a significant outcome difference that is attributed to a treatment but is actually because of a confounding factor such as diet. It is therefore important for such nonrandomized trials to be multicentered and involve a sufficiently large population to partially compensate for this bias. If possible, all procedures being tested should be performed at all institutions to minimize bias because of geographic or socioeconomic factors or perioperative care differences.
Selection bias will be of even greater concern in these and in randomized studies if a surgeon, in these cases necessarily unblinded, selects patients for study inclusion on the basis of criteria that are not part of the study. Consider the NSABP study comparing the effectiveness of total mastectomy to segmental mastectomy to segmental mastectomy with radiation. 12 If this had been done as a surgeon allocated study, rather than a randomized one, and a surgeon who had chosen segmental mastectomy as his/her preferred operation had decided not to offer participation to women over age 60, that action would have biased the results, affecting internal validity. To avoid such a situation, these nonrandomized surgeon allocation trials should have surgeons account for each patient who is not asked to enroll or who chooses not to enroll, with their reasons for doing so. As this minimizes selection bias, it is a good safeguard for all controlled trials, whether randomized or not.
A discussion of performance bias is incomplete without mention of surgical skill. A full discussion of what constitutes surgical skill and how to measure it is beyond this article. Though it seems intuitive that surgical skill should correlate with outcome, there is no evidence that it does. What studies have shown is that, as a rule, skill correlates with general surgical experience and knowledge as well as understanding of and familiarity with a given procedure, 34, 35 a factor that has already been dealt with. Although it may be true that there are some unique surgeons of extraordinary skill, and vice versa, that type of outlier performance does not translate into external validity.
Elimination of performance bias requires an intervention to have a fixed nature and uniform action. An evolving, innovative procedure or device lacks such constancy. 36 Until a device/procedure's key development stabilizes, trials of such devices/procedures will necessarily be too small for statistical significance and thus will lack both internal and external validity. In examining such studies and deciding whether or not to incorporate their results into clinical practice, surgeons should remember that and inform their patients of the uncertainty about such treatments' effectiveness and safety.
BIAS AFTER A TRIAL ENDS Citation Bias
Research is translated into practice not by 1 trial but by an accumulation of RCT and observational trial data that convinces a clinician that a given intervention is best for an individual patient's condition. How trial results are reported influences that perception. Distorted trial reporting, called citation bias, biases clinicians' judgment of an intervention's applicability and can make it difficult to assess a trial's internal and external validity. Clinicians' opinion of what to expect from an intervention can be warped by reporting only trials favorable toward an intervention. 37, 38 This is trial selection bias (Table 4) . It occurs because publishers, researchers, and sponsors are reluctant to publish unfavorable trials. 39 To address this problem, in 2004, the International Committee of Medical Journal Editors (ICMJE) began to require that, to be published, an RCT must be registered. 40 In 2007, they expanded this criteria to include all trials that "prospectively assign participants to a health-related intervention to evaluate effects on health outcomes" and which begin enrollment after July 1, 2008. These requirements do not include purely observational trials, 41 which the ICMJE defines as a research project that does not "prospectively assign human subjects to an intervention or concurrent comparison group to study the cause-and-effect relationship between that intervention and a health outcome." 42 A goal of this dictum is to provide a mechanism to learn of unpublished trials that show less favorable findings about an intervention. It does not guarantee that such trials will be published or even that the public will have access to data from them. It only has the potential to create awareness that such unpublished trials exist and thus provoke further questions about an intervention.
Similarly, duplicate publishing misleads clinicians into thinking there is more evidence to support an intervention than actually exists. Covert evidence manipulation is especially difficult to detect if the first author and the number of authors differ in repetitive publications. Though duplicate publishing can be useful for analyzing trials in different ways, it is essential that such duplications explicitly reference other publications reporting on the same trial. 43 The trial registries that the ICMJE champions provide a database that may help uncover such practices. 44 And, though attentive editors and reviewers try to act as gatekeepers to prevent these practices, the concealment's nature means there is no fool-proof detection system.
As discussed, to assess a trial's external and internal validity, clinicians need information about a trial's design and conduct. Incomplete trial information makes this difficult. Many trial reports lack important information such as clearly defined endpoints and inclusion and exclusion criteria and are nonspecific about randomization, blinding procedures, and/or sample size calculations. [45] [46] [47] [48] These deficits are more preva- 
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Bias in Surgical Research lent in surgical than in medical intervention trial reports. Of particular importance to surgeons, surgical intervention details such as anesthetic management, preoperative and postoperative care, a surgeon's experience with a procedure, and a hospital's surgical volume are less likely than not to be reported. Affecting external validity, this makes it more difficult to confidently translate research into practice. 49, 50 For instance, in the hypothetical hand irrigation study, if important injury details, such as bone fractures, were not included, a surgeon might find it difficult to know if he/she could expect the same results in patients with bone fractures. And, if in the same study subjects were only enrolled if their surgery occurred during the regular operating room weekday schedule and only if a certain nurse was available to set up the irrigation system, the selection bias that created would affect the study's internal validity.
The ICMJE, by specifying a minimal data set that must be included when registering a trial, addresses some of these reporting problems. That data set is, however, very basic. For example, although it does include target sample size, it does not ask how that number was calculated. 51 The Consolidated Standards of Reporting Trials (CONSORT) statement, developed in 1996 and modified in 2001, has a more complete set of reporting criteria. It requires, for instance, details about how randomization was done, precise details of interventions, and a listing of all important adverse events and protocol deviations. 52 Though ICMJE has endorsed the CONSORT statement, no journal mandates its use, and only a few mentions it in their instructions to authors. 53, 54 Where the CONSORT statement has been adopted, RCT reporting has improved. 55, 56 However, the CONSORT statement applies only to RCTs, not to observation trials that are more prevalent in surgery. 57 Argument about the place of observation trials and RCTs in assessing surgical interventions is beyond this article. However, given that well-conducted observation trials provide valuable information about long-term outcomes and adverse effects in a range of patients, a matter of special importance to surgeons, 58, 59 developing similar observation trial guidelines would provide an invaluable aid for assessing observation trial reports. Such guidelines could address issues such as assessment of surgical expertise and facility capabilities, and innovative procedure research.
OVERARCHING BIASES
To this point, we have discussed issues that create bias in the design, execution, and reporting of a research trial. There are also overall environmental issues such as conflicts of interest and society's attitude toward research that may facilitate bias (Table 5) .
Optimism Bias
The belief that new therapies are better than established ones, optimism bias, influences both investigators and subjects. Such bias is based, not on reality, but on unrealistic hope. 60 It can bias subjective evaluations of outcome as in the hypothetical knee motion example. And it can interfere with subjects' and investigators' equipoise, making it difficult to enroll subjects in trials comparing a new, but not fully investigated therapy, to conventional therapy. Optimism bias sabotaged the RCT that investigated the efficacy of high-dose chemotherapy and autologous stem-cell transplant (HDCT and ASCT) compared with conventional chemotherapy in treating breast cancer. Patients' unwarranted belief that HDCT and ASCT would be more effective than conventional chemotherapy made them reluctant to risk receiving conventional chemotherapy in an RCT. Instead, they pursued HDCT and ASCT treatment outside clinical trials. The resulting slow trial accrual meant that by the time the trial was completed, the chemotherapy protocol that had been used was outdated and the data had limited applicability to current treatment protocols. 61, 62 Optimism bias can lead to new treatment procedures, unsupported by evidence, subverting evidence production, and undermining research's ability to produce scientifically valid evidence.
Optimism bias may be fostered by and contribute to citation bias. Ioannidis, in 2005, published an article analyzing highly cited articles (receiving Ͼ1000 citations) compared with those less frequently cited (receiving an average of 157 citations). The more articles were cited the significantly more likely they were to report positively on a new intervention. Ironically, the same study found that a third of the highly cited research was subsequently contradicted or shown to have a lesser effect than initially reported. 63 Given this, how can patient/subjects and physician/researchers be faulted for believing that what is new is always better?
Conflicts of Interest
Conflicts of interest have been defined as "a set of conditions in which professional judgment concerning a primary interest (eg, patient welfare, research validity) may be unduly influenced by a secondary interest (eg, financial gain)." 64 We have discussed the various ways in which trial validity can be biased by such features as design, selection criteria, data collection, choice of comparator group, and reporting. Conflicts of interest can affect the decision-making involved in any of these processes, either consciously or subconsciously. Though discussions of conflicts of interest have focused mostly on financial secondary interests, other secondary interests, such as academic prestige and career advancement, may also have the potential to bias a trial.
A recent study looked at RCTs published in the British Medical Journal from June 1997 to June 2001. The secondary interests, defined as those the authors declared included academic, personal, and political potential conflicts as well as for-profit funding. They found that authors' conclusions were significantly more positive toward an experimental intervention only if a for-profit organization was their funding source. This was not seen with other competing interests and was not explained by trial methodology, statistical power, or control 65 This is consistent with other studies. 15, 66, 67 This association does not necessarily mean that there this is evidence for a cause and effect relationship.
Fries, in a review of articles presented at the American College of Rheumatology's annual meeting in 2001, found a similar association between a for-profit study sponsor and research findings favorable to a sponsor's product. Of 45 for-profit company sponsored studies, 32 had a placebo group, and 3 of the 22 trials with an active comparator group were based on a previous RCT with a different endpoint. He argued that this is a cause and effect relationship that there is design bias in such studies and that these trials were designed to produce the results the sponsors wanted. He contended that such bias is desirable because it makes studies more efficient and exposes subjects to less risk. 68 It may be true that for-profit companies are unlikely to incur the expense of investigating an intervention that they think is unlikely to be shown to be effective, which does not necessarily mean that trials "designed" to favor a particular intervention will prove to be consistent with what happens outside of a trial, ie, have external validity. For instance, in the hand irrigation trial, the absence of wound drainage at 6 weeks may have been chosen as the endpoint because it reveals a difference in the 2 study groups that would not be seen if a different endpoint was used. Design bias, that is designing a trial to assure a specific outcome, can invalidate a trial both internally and externally, providing physicians and patients with erroneous information that can harm patients.
Conflicts of interest in research are inevitable. That does not mean that they cannot be managed or necessarily will result in bias. They are, after all, an existing condition, not a form of behavior. 69 One way to manage such conflicts lies in trial design and execution. Blinding, by minimizing selection, detection and ascertainment biases, can help to prevent corruption of trial outcomes. Randomization can reduce selection bias. Finally, disclosure of conflicts of interest may allow those assessing trial results to consider whether they should examine that trial with reserve. It is important that such disclosures address the nature of the conflict, not just its existence. 64 For instance, does a researcher have equity interests in a trial's for-profit sponsor, does he/she teach a course using one of the sponsor's products, did he/she receive an award from the sponsor through his/her professional society? How these different scenarios influence trial conduct is unknown. It is an area that requires research so as to better assess the influence of various conflicts and design methods to manage them.
CONCLUSIONS
To assess research's bias and its effects on internal and external validity, surgeons need information about comparator groups' applicability and about design issues such as selection criteria, randomization, blinding, and the reliability of surrogate endpoints. They should be aware of conflicts of interest. Surgeons' need for this information does not differ from that of other clinicians. What is different is the prevalence of observational studies in surgery and the difficulty of blinding surgical studies, standardizing interventions, and randomizing patients. Considerations of subject safety, feasibility, cost, and the reality of an ever changing environment make biases an inevitable feature of research. Surgeons need to pay attention to how the features unique to surgery, as well as those common to all research, were approached in a surgical trial and the rationale and effect of those approaches. It is that assessment that will enable them to answer the questions of how believable the research is and whether and when they can use it in their practices.
In order for surgeons to interpret and use surgical research results in their practices to best benefit their patients they need sufficient access to research details. Publications that use the CONSORT statement improve access to such information. Though those criteria apply to RCTs, which are less commonly done to evaluate surgical interventions, some of the principles that the statement embodies can be applied to other types of surgical research. There is, however, a need for surgical researchers to develop additional criteria to guide surgical research assessment and publication.
